Affinity Asset Advisors, LLC Black Diamond Therapeutics, Inc. Transaction History
Affinity Asset Advisors, LLC
- $560 Million
- Q4 2024
A detailed history of Affinity Asset Advisors, LLC transactions in Black Diamond Therapeutics, Inc. stock. As of the latest transaction made, Affinity Asset Advisors, LLC holds 559,163 shares of BDTX stock, worth $1.27 Million. This represents 0.21% of its overall portfolio holdings.
Number of Shares
559,163Holding current value
$1.27 Million% of portfolio
0.21%Shares
2 transactions
Others Institutions Holding BDTX
# of Institutions
94Shares Held
47.6MCall Options Held
2.9KPut Options Held
69.4K-
T. Rowe Price Investment Management, Inc. Baltimore, MD10.5MShares$23.9 Million0.01% of portfolio
-
Bellevue Group Ag Kuesnacht, V88.52MShares$19.4 Million0.36% of portfolio
-
Vestal Point Capital, LP New York, NY5.6MShares$12.8 Million0.71% of portfolio
-
Nea Management Company, LLC Timonium, MD4.45MShares$10.1 Million0.68% of portfolio
-
Black Rock Inc. New York, NY3.22MShares$7.34 Million0.0% of portfolio
About Black Diamond Therapeutics, Inc.
- Ticker BDTX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 36,339,500
- Market Cap $82.9M
- Description
- Black Diamond Therapeutics, Inc., a biotechnology company, discover, develops, and commercializes medicines for patient with genetically defined tumors. It develops BDTX-189, an irreversible small molecule inhibitor that is designed to targets oncogenic proteins defined by the non-canonical epidermal growth factor receptor (EGFR) and human epide...